Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
EyeBio
United Kingdom
- London
- 15/11/2023
- Series A
- $65,000,000
EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
- Industry Biotechnology Research
- Website https://eyebiotech.com/
- LinkedIn https://www.linkedin.com/company/eyebio/about/
Related People
David GuyerFounder
United States -
New York City Metropolitan Area
David Guyer, MD has been a CEO of two public biotech companies, a Partner in a major Venture Capital fund, and Professor and Chairman of the Ophthalmology Department at the NYU School of Medicine. He has over 30 years experience in drug development as a CEO, venture capitalist, and academician.
He developed and commercialized the first anti-VEGF drug for macular degeneration as the co-founder and CEO at EyeTech. He has taken two companies public and served on approximately 20 Boards. David has also consulted extensively for many companies. He has done numerous large partnering and M&A deals.
David is presently serving on multiple boards and consulting with numerous biotech companies.
Cintoo | $40,246,701 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Persperity Health, Inc | $1,000,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)